Inner-Ear AAV Gene Therapy to Preserve Cells for Cochlear Implants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hearing loss, particularly due to genetic mutations in TMPRSS3 and LOXHD1 genes, are inadequate, with cochlear implants providing limited effectiveness and high costs, and there is a lack of approved therapeutic agents for preventing or treating hearing loss.
Innovation Solution
A combination of gene therapy using adeno-associated viral vectors to deliver functional TMPRSS3 or LOXHD1 genes to the inner ear, potentially combined with cochlear implants, to restore hair cell and spiral ganglion cell function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cochlear implants are used to treat hearing loss, then hearing function can be restored, but the treatment cost is prohibitively high and effectiveness is limited
Solution Approach 1:
The treatment is segmented into two components: gene therapy to preserve spiral ganglion cells and cochlear implant to restore hearing function. This segmentation allows the gene therapy component to potentially reduce the overall treatment cost and improve effectiveness by preserving native cells, while the cochlear implant provides reliable hearing restoration.
Solution Approach 2:
Gene therapy is administered as a preliminary action before cochlear implantation to preserve spiral ganglion cells. This preliminary gene delivery prevents further degeneration of auditory neurons, creating a better foundation for subsequent cochlear implant function and potentially reducing long-term treatment costs.
2Reliability
If cochlear implants are used to treat hearing loss, then hearing function can be restored, but the demand exceeds supply and production is limited
Solution Approach 1:
By segmenting the treatment into gene therapy and cochlear implant components, the patent reduces dependence on cochlear implant production alone. Gene therapy can be administered to preserve spiral ganglion cells in patients who would otherwise require cochlear implants, effectively increasing treatment availability without being constrained by implant production rates.
Solution Approach 2:
Gene therapy acts as an intermediary treatment that preserves spiral ganglion cells, thereby improving the effectiveness and availability of cochlear implant treatment. This intermediary approach ensures that more patients can benefit from cochlear implants by maintaining a healthier auditory nerve substrate, effectively increasing treatment availability without requiring increased implant production.
3Ease of manufacture
If gene therapy is used to treat hearing loss, then treatment cost can be reduced, but the effectiveness may be insufficient without cochlear implant combination
Solution Approach 1:
The patent merges gene therapy and cochlear implant treatments into a combined therapeutic approach. Gene therapy delivers functional copies of TMPRSS3 or LOXHD1 genes to preserve spiral ganglion cells, while cochlear implants restore hearing function. This combination achieves both cost-effectiveness and high treatment effectiveness by leveraging the strengths of both approaches.
Solution Approach 2:
Gene therapy is administered as a preliminary action to preserve spiral ganglion cells before cochlear implantation. This preliminary gene delivery ensures that the auditory nerve is in optimal condition to receive and process cochlear implant signals, thereby maximizing treatment effectiveness while maintaining cost advantages over cochlear implants alone.
Data Source
AI summary
The present disclosure describes gene therapy systems, and related methods, useful for treating and/or preventing deafness caused by genetic mutation of the TMPRSS3 gene or the LOXHD1 gene. The compositions and methods disclosed herein use adeno-associated viral (AAV) vector gene delivery of TRMPSS3 or LOXHD1 into the inner ear to restore activity of the TMPRSS3 gene or the LOXHD1 gene, respectively, promote hair cell survival and restore hearing in patients suffering from hearing loss. As disclosed herein, the systems and methods may utilize a combination of gene therapy (e.g., molecular therapeutics) for hearing loss caused by a genetic mutation together with implantation of a cochlear implant.